SOMERVILLE, Mass.--(BUSINESS WIRE)--Dec 6, 2025--

Genetix Biotherapeutics Inc. today announced their participation in the American Society of Hematology’s (ASH) exclusive press program ahead of the 67 th ASH annual meeting in Orlando, Florida (December 6-9, 2025). Genetix’s abstract Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia was selected by the ASH Program Committee as one of the meeting’s most impactful datasets submitted this year.

“We’re honored to be selected for ASH’s exclusive program, a recognition that underscores the significance of our data, which is the first to analyze commercial gene therapy adoption for the treatment of hemoglobinopathies,” said Joanne Lager, MD, Chief Medical Of

See Full Page